{
  "first_published_at": "2010-06-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085088", 
  "title": "Bevacizumab (Avastin): hypersensitivity and infusion reactions", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 195, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Bevacizumab (Avastin): hypersensitivity and infusion reactions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Healthcare professionals are advised to be aware that infusion reactions and hypersensitivity reactions have been reported commonly (&#8805;1/100&#8211;&lt;1/10) during treatment with Avastin.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Bevacizumab</strong> (Avastin) is a monoclonal antibody, which inhibits vascular endothelial growth factor and is authorised for the treatment of various metastatic cancers.</p><p>Healthcare professionals are advised to be aware that infusion reactions and hypersensitivity reactions have been reported commonly (&ge;1/100&ndash;&lt;1/10) during treatment with Avastin. The incidence of such reactions is estimated to be up to 5% in clinical trials. Symptoms reported have included dyspnoea, flushing, rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors, and nausea or vomiting. These reactions normally resolve quickly if the infusion is stopped immediately. Treatment with corticosteroids, antihistamines, oxygen, and intravenous fluids may also be administered as clinically indicated.</p><p><a href=\"ssLINK/CON081746\">Further information is available in a letter for healthcare professionals sent in April 2010</a>.</p><p><em>Article citation: Drug Safety Update June 2010, vol 3 issue 11: 5.</em>&nbsp;</p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Bevacizumab</strong> (Avastin) is a monoclonal antibody, which inhibits vascular endothelial growth factor and is authorised for the treatment of various metastatic cancers.</p><p>Healthcare professionals are advised to be aware that infusion reactions and hypersensitivity reactions have been reported commonly (&#8805;1/100&#8211;&lt;1/10) during treatment with Avastin. The incidence of such reactions is estimated to be up to 5% in clinical trials. Symptoms reported have included dyspnoea, flushing, rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors, and nausea or vomiting. These reactions normally resolve quickly if the infusion is stopped immediately. Treatment with corticosteroids, antihistamines, oxygen, and intravenous fluids may also be administered as clinically indicated.</p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746\">Further information is available in a letter for healthcare professionals sent in April 2010</a>.</p><p><em>Article citation: Drug Safety Update June 2010, vol 3 issue 11: 5.</em>&#160;</p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-06-01", 
  "date_last_modified": "2010-09-14", 
  "_assets": [], 
  "_item_id": 195, 
  "summary": "", 
  "body": "Article date: June 2010\n\nBevacizumab (Avastin) is a monoclonal antibody, which inhibits vascular endothelial growth factor and is authorised for the treatment of various metastatic cancers.\n\nHealthcare professionals are advised to be aware that infusion reactions and hypersensitivity reactions have been reported commonly (≥1/100–<1/10) during treatment with Avastin. The incidence of such reactions is estimated to be up to 5% in clinical trials. Symptoms reported have included dyspnoea, flushing, rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors, and nausea or vomiting. These reactions normally resolve quickly if the infusion is stopped immediately. Treatment with corticosteroids, antihistamines, oxygen, and intravenous fluids may also be administered as clinically indicated.\n\n[Further information is available in a letter for healthcare professionals sent in April 2010](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746).\n\nArticle citation: Drug Safety Update June 2010, vol 3 issue 11: 5. \n"
}